SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
1.04%178.150.4%$133.79m
PRGOPerrigo Co. Plc
0.59%73.006.8%$96.94m
JAZZJazz Pharmaceuticals Plc
0.57%161.932.2%$71.31m
MNKMallinckrodt Plc
0.37%29.7821.1%$71.12m
ENDPEndo International Plc
0.57%15.948.9%$59.14m
PTLAPortola Pharmaceuticals, Inc.
-0.49%28.267.7%$39.30m
UTHRUnited Therapeutics Corporation
0.21%126.2014.4%$38.96m
SAGESAGE Therapeutics, Inc.
1.26%146.969.6%$37.47m
CTLTCatalent Inc
0.73%42.882.4%$36.06m
GWPHGW Pharmaceuticals PLC Sponsored ADR
5.86%149.206.8%$34.56m
ICPTIntercept Pharmaceuticals, Inc.
1.54%120.6018.7%$32.16m
ZGNXZogenix, Inc.
0.31%48.6511.9%$29.41m
SUPNSupernus Pharmaceuticals, Inc.
1.96%46.906.2%$27.84m
MDCOMedicines Company
0.30%33.6621.8%$24.85m
ICLRICON Plc
0.95%146.654.2%$23.87m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.